Skip to content

INHIBIKASE THERAPEUTICS, INC.

IKT

CIK 0001750149

← back to feed
Revenue (TTM)
$0
−100.0% YoY Q1 May 2026
Net Income (TTM)
−$51.91M
−75.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.49
+57.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$26.02M
Q1 May 2026
Cash
$178.8M
Q1 May 2026
Total Debt
$381.78K
Q1 May 2026
Shares Outstanding
132.03M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings